Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Exp Hematol. 2007 Apr;35(4):587–595. doi: 10.1016/j.exphem.2006.12.007

Table 1.

Frequency of JAK2V617F during in vitro expansion of PV erythroid progenitors: Genomic DNA was isolated from cells from each of the three steps during in vitro expansion of erythroid progenitors. JAK2V617F was quantitated in granulocytes as well as the erythroid progenitors as described.

Patients T-status GNC S1 S2 S3 % Dec
1 G/T 65 9 15 9 86
2 T/T 97 19 13 18 81
3 G/T 52 5 13 13 75
4 T/T 97 41 29 30 70
5 T/T 79 36 31 24 70
6 G/T 28 7 15 11 61
7 T/T 83 36 43 39 53
8 T/T 89 40 61 52 42
9 T/T 81 42 82 66 20
10 T/T 84 48 66 68 19
11 G/T 47 21 31 41 13
12 T/T 86 70 74 79 8
13 T/T 96 90 93 91 5
14* G/T 37 19 37 37 0
15** G/T 50 47 44 50 0
*

(Patient #14 is a five-year old female PV patient).

**

(Patient #15 has idiopathic myelofibrosis). Percent decrease in JAK2V617F in the terminal step of erythroid expansion is calculated relative to the JAK2V617F in the corresponding granulocytes (100%).